This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Neurology 1996;46:4-8
Based on initial descriptions, Machado-Joseph disease (MJD) was thought to be a distinct clinicopathologic entity. This autosomal dominant disorder was originally described in the Machado family on the Azorean island of San Miguel, [1] in the Thomas family, which had migrated from San Miguel to Massa-chusetts, [2] and in the Joseph family, which had migrated from the Azorean island of Flores to California. [3] These families were initially considered to have distinct phenotypes, but it was soon recognized that the diverse phenotypes occurred within each family and that all three families had the same disorder. [4] The disorder, initially felt to be limited to Azorean and Portuguese families, has occurred in families of diverse ethnic origins on five continents. [5]
The most common classification of MJD divides patients into three phenotypes. [5] Cerebellar ataxia and ophthalmoplegia are common to all types. Type 1 has an early symptom onset, typically around 25 years, and is additionally characterized by pyramidal signs and dystonic postures. Type 2, the most common type, occurs around middle age (mean, 40 yr) and is dominated by ataxia and ophthalmoplegia, with or without pyramidal signs. Type 3 is later in onset (mean, 47 yr) and progresses slowly with prominent amyotrophy. Other findings that may help in diagnosis include facial and lingual fasciculations and staring due to lid retractions, each seen in a minority of patients. The pathology differs some-what from that of other hereditary ataxias, with sparing of the inferior olivary nuclei and Purkinje cells but substantial involvement of the dentate nuclei and substantia nigra. [5]
Spinocerebellar ataxia type 3 (SCA3), in contrast, was never believed to be clinically or pathologically distinct, but was distinguished from other dominantly inherited ataxias by its linkage to chromosome 14q. Among the autosomal dominant ataxias, recent years have witnessed genetic …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
